0A6R Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementAdvancing into the final cohort demonstrates continued execution of the Hemopurifier clinical program and provides a defined path toward completing current human studies. The absence of device-related serious safety events in the reported participant supports continued development, although efficacy remains unproven.
Platform Expansion And Scientific SupportEvaluating the Hemopurifier across multiple disease areas increases the platform’s potential addressable applications beyond oncology and viral infections. Continued experiments, publication activity and intellectual-property generation can strengthen strategic options if clinical validation supports broader use.
Operating Cost DisciplineLower operating expenses show management is controlling the cost base while advancing clinical work, which can extend available resources and reduce the pace of cash consumption. Sustained discipline would improve the company’s ability to prioritize high-value development activities before commercialization.
Bears Say
No Demonstrated Commercial RevenueThe absence of a recurring commercial revenue base leaves Aethlon dependent on future product validation, regulatory progress and external financing rather than operating cash inflows. Persistent losses also mean the business has not yet demonstrated sustainable earnings power or operating leverage.
Preliminary Clinical EvidenceVery small cohorts limit statistical power and make the reported biomarker changes difficult to generalize across patients or indications. Until larger studies confirm reproducibility and establish clinical benefit, the Hemopurifier’s commercial and regulatory prospects remain materially uncertain.
Funding Needs For Larger TrialsThe current financing and stated runway support near-term operations but do not remove the need for additional resources to conduct larger efficacy trials. Dependence on future capital, partnerships or grants can slow development and may constrain the company’s ability to pursue multiple indications.
Aethlon Medical News
0A6R FAQ
What was Aethlon Medical Inc’s price range in the past 12 months?
Currently, no data Available
What is Aethlon Medical Inc’s market cap?
Aethlon Medical Inc’s market cap is €1.11M.
When is Aethlon Medical Inc’s upcoming earnings report date?
Aethlon Medical Inc’s upcoming earnings report date is Nov 18, 2026 which is in 71 days.
How were Aethlon Medical Inc’s earnings last quarter?
Aethlon Medical Inc released its earnings results on Aug 13, 2026. The company reported -€3.472 earnings per share for the quarter, missing the consensus estimate of -€3.39 by -€0.082.
Is Aethlon Medical Inc overvalued?
According to Wall Street analysts Aethlon Medical Inc’s price is currently Undervalued.
Does Aethlon Medical Inc pay dividends?
Aethlon Medical Inc does not currently pay dividends.
What is Aethlon Medical Inc’s EPS estimate?
Aethlon Medical Inc’s EPS estimate is -2.33.
How many shares outstanding does Aethlon Medical Inc have?
Currently, no data Available
What happened to Aethlon Medical Inc’s price movement after its last earnings report?
Aethlon Medical Inc reported an EPS of -€3.472 in its last earnings report, missing expectations of -€3.39. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Aethlon Medical Inc?
Currently, no hedge funds are holding shares in GB:0A6R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aethlon Medical Inc
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
0A6R Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced tangible near-term progress with clear caveats. Positives include advancement into the final clinical cohort, encouraging Cohort 2 biomarker signals, a peer-reviewed Long COVID preclinical publication, ongoing R&D expansion, an improved post-quarter cash position following a ~$4.0M financing, and an 11.9% reduction in operating expenses. Key negatives are that clinical observations are preliminary and based on very small sample sizes, statistical analyses are pending, dosing is logistically constrained, and larger trials will require additional capital or partnerships. Overall, the company shows disciplined resource management and meaningful early scientific signals but faces validation, scale and funding headwinds before efficacy or regulatory clarity can be established.View all GB:0A6R earnings summaries